Health-Related Quality of Life in Patients With Giant Cell Arteritis Treated With Tocilizumab in a Phase 3 Randomized Controlled Trial: GiACTA

Vibeke Strand,1 Sophie Dimonaco,2 Katie Tuckwell,3 Micki Klearman,3 Neil Collinson,3 and John H. Stone4 for the GiACTA Investigators

Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, USA; 2Roche Products Ltd., Welwyn Garden City, United Kingdom; 3Genentech, South San Francisco, CA, USA; 4Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, USA

INTRODUCTION

OBJECTIVE

METHODS

RESULTS

Figure 4. Marked improvements in MCS and PtGA scores (Figure 9)• Weekly tocilizumab 162 mg plus 26-week prednisone taper resulted in significant improvements in PCS and 4 domains of SF-36 compared with a 52-week course of prednisone (Figure 7).• Patients treated with weekly tocilizumab consistently reported improvements that were clinically meaningful (MCIDs) in SF-36 PCS, SF-36 MCS, and FACIT-Fatigue scores compared with PBO+52 and baseline age-gender matched reference values (Figure 5, 6).• Patients treated with weekly tocilizumab reported multiplicative improvements, particularly in PCS and MCS (Figure 4).• At week 52, patients in the TCZ QW group reported statistically greater scores (Figure 4)• Compared with age- and gender-matched norms (SF-36 domains).• MCIDs for each outcome are shown in parentheses. • Patients treated with weekly tocilizumab consistently reported improvements that were clinically meaningful (MCIDs) in SF-36 PCS, SF-36 MCS, and FACIT-Fatigue scores compared with a 52-week course of prednisone (Figure 7).• Patients treated with weekly tocilizumab reported multiplicative improvements, particularly in PCS and MCS (Figure 4).• At week 52, patients in the TCZ QW group reported statistically greater scores (Figure 4)

Figure 5. Median cumulative prednisone dose for TCZ QW (n = 82-85) PBO+26 (n = 48) PBO+52 (n = 49-51)

Figure 6. Significant improvements in PtGA and FACIT-Fatigue scores (Figure 4)• Patients treated with weekly tocilizumab reported improved PtGA and FACIT-Fatigue scores compared with PBO+52 and baseline age-gender matched reference values (Figure 5, 6).• Patients treated with weekly tocilizumab reported multiplicative improvements, particularly in PtGA and FACIT-Fatigue (Figure 4).• At week 52, patients in the TCZ QW group reported statistically greater scores (Figure 4)

Figure 7. Significant improvements in physical function (PF) and social function (SF-36) scores (Figure 4)• Patients treated with weekly tocilizumab reported improved PF and SF-36 scores compared with PBO+52 and baseline age-gender matched reference values (Figure 5, 6).• Patients treated with weekly tocilizumab reported multiplicative improvements, particularly in PF and SF-36 scores (Figure 4).• At week 52, patients in the TCZ QW group reported statistically greater scores (Figure 4)

Figure 8. Improvements in MCID categories for SF-36 pain and functional status (Figure 4)• Patients treated with weekly tocilizumab reported improvements in functional status and pain compared with PBO+52 and baseline age-gender matched reference values (Figure 5, 6).• Patients treated with weekly tocilizumab reported multiplicative improvements, particularly in functional status and pain (Figure 4).• At week 52, patients in the TCZ QW group reported statistically greater scores (Figure 4)

Figure 9. Improvements in MCID categories for SF-36 pain and physical function (Figure 4)• Patients treated with weekly tocilizumab reported improvements in physical function and pain compared with PBO+52 and baseline age-gender matched reference values (Figure 5, 6).• Patients treated with weekly tocilizumab reported multiplicative improvements, particularly in physical function and pain (Figure 4).• At week 52, patients in the TCZ QW group reported statistically greater scores (Figure 4)

DISCUSSIONS

REFERENCES

This study was funded by F. Hoffmann-La Roche Ltd.
Support for third-party writing assistance for this paper was provided by F. Hoffmann-La Roche Ltd.